Major depressive disorder (MDD) is a mental health condition that goes well beyond ordinary sadness. It involves persistent changes in mood, energy, thinking, and behavior that last at least two weeks and interfere with daily life. About 21 million adults in the United States experience at least one major depressive episode per year, roughly 8.3% of the adult population.
How It Differs From Normal Sadness or Grief
Everyone feels sad, and grief after a loss is a natural human experience. But major depression is distinct in several ways. In grief, painful feelings tend to come in waves and are often mixed with positive memories. In depression, mood stays almost constantly negative. Grief usually leaves your self-esteem intact. Depression corrodes it, bringing persistent feelings of worthlessness and self-loathing. If someone who is grieving also develops symptoms like suicidal thoughts (beyond simply wanting to be with a lost loved one), a sense of worthlessness, or a collapse in overall functioning, that points toward a depressive episode layered on top of the grief.
Core Symptoms
A diagnosis requires five or more specific symptoms present during the same two-week period. At least one of those symptoms must be either a persistently depressed mood or a loss of interest or pleasure in activities you used to enjoy. The remaining symptoms include:
- Appetite or weight changes in either direction, gaining or losing without trying
- Sleep problems, either insomnia or sleeping far more than usual
- Psychomotor changes, meaning you feel physically slowed down or restless and agitated in a way others can notice
- Fatigue or loss of energy, even when you haven’t exerted yourself
- Difficulty thinking, concentrating, or making decisions
- Feelings of worthlessness or excessive guilt
- Recurrent thoughts of death or suicide
These symptoms have to be severe enough to cause real problems at work, in relationships, or in basic self-care. A few rough days after a breakup wouldn’t qualify. The pattern needs to be sustained and impairing.
Who Is Most Affected
Depression does not hit all groups equally. Women are significantly more likely to experience it than men: 10.3% of adult women versus 6.2% of adult men. The age group hit hardest is young adults aged 18 to 25, where the rate reaches 18.6%. It drops to 9.3% among adults 26 to 49 and falls further to 4.5% among those 50 and older.
Among adolescents, the numbers are striking. About 20% of all 12- to 17-year-olds in the U.S. had at least one major depressive episode in 2021. Nearly 29% of adolescent girls experienced one, compared to 11.5% of boys. Rates also climb with age through adolescence, from 13% among 12- to 13-year-olds to nearly 27% among 16- to 17-year-olds.
What Happens in the Brain
Depression involves disruptions in several chemical messaging systems in the brain. The three most studied are serotonin, norepinephrine, and dopamine, and each one maps onto different symptom clusters.
Low serotonin activity is linked to the emotional core of depression: persistent sadness, self-criticism, irritability, anxiety, and insomnia. Serotonin problems in depression involve both reduced production of the chemical and abnormal function of the receptors that receive its signal. When certain serotonin receptors in the brain’s fear-processing center (the amygdala) become overactive, the result can be heightened anxiety, panic, and disrupted sleep.
Norepinephrine fuels alertness, energy, and the capacity for pleasure. When norepinephrine function drops, people lose interest in things, feel drained, and struggle to experience happiness. Paradoxically, under chronic stress, a different norepinephrine pathway can become overactive, triggering anxiety and hypervigilance. This helps explain why depression and anxiety so often travel together.
Dopamine drives motivation, the ability to feel reward, concentration, and psychomotor speed. When dopamine signaling falters, the result is hopelessness, loss of interest, and difficulty concentrating. Reduced dopamine activity in the prefrontal cortex also weakens its ability to keep the amygdala in check, which can amplify fear and anxiety.
Several brain regions are consistently involved, including the prefrontal cortex (responsible for decision-making and emotional regulation), the amygdala (which processes threat and emotion), and the hippocampus (important for memory and stress regulation).
Subtypes of Depression
Not all major depression looks the same. Clinicians use specifiers to describe particular patterns. Seasonal affective disorder involves depressive episodes that follow a seasonal pattern, most commonly worsening in fall and winter. Atypical depression is marked by mood that temporarily lifts in response to good news, along with increased appetite, excessive sleeping, heavy feelings in the arms and legs, and sensitivity to rejection. Peripartum depression includes episodes that begin during pregnancy or in the weeks after delivery. Recognizing the specific subtype helps guide treatment choices.
Psychotherapy Options
Three forms of talk therapy have the strongest evidence for treating depression, all recommended by the American Psychological Association.
Cognitive-behavioral therapy (CBT) targets the relationship between thoughts, feelings, and behavior. The core idea is that distorted thinking patterns fuel depressive feelings and withdrawal from life, and that changing those patterns improves mood and functioning. It is structured, typically time-limited, and focuses on current problems rather than childhood origins.
Behavioral activation takes a more direct approach. It focuses on getting you re-engaged in activities you once found pleasurable or meaningful, even before your mood improves. The theory is that activity drives mood rather than the other way around. Over time, increased participation in rewarding activities lifts depression and restores functioning.
Interpersonal therapy (IPT) zeroes in on your relationships. Depression often develops in the context of conflict, loss, life transitions, or social isolation. IPT teaches strategies for communicating emotions and needs more effectively and solving problems within key relationships. As those relationships improve, depressive symptoms often ease.
Medication
The most commonly prescribed antidepressants are SSRIs, which stands for selective serotonin reuptake inhibitors. Normally, after serotonin carries a signal between brain cells, it gets pulled back into the cell that released it. SSRIs block that recycling process, leaving more serotonin available in the gap between cells to keep transmitting signals. This is why they typically take several weeks to reach full effect: the brain needs time to adapt to the new chemical environment.
Another class, SNRIs, works on both serotonin and norepinephrine, which can help when fatigue and low motivation are dominant symptoms. Older classes of antidepressants exist as well, though they tend to have more side effects and are generally used when newer options haven’t worked.
Many people respond well to the first or second medication they try. But for a significant minority, roughly one in three, multiple conventional antidepressants fail to produce remission or even a 50% improvement in mood.
When Standard Treatments Don’t Work
If you’ve tried at least two antidepressants for six weeks each without meaningful improvement, the clinical term is treatment-resistant depression. This isn’t a dead end, but it does change the conversation about next steps.
One option that has gained traction is esketamine, a nasal spray derived from the anesthetic ketamine. Unlike traditional antidepressants that take weeks to build up, esketamine acts on brain cells immediately and can reduce depressive symptoms within hours. In clinical trials, it helped a majority of people whose depression hadn’t responded to conventional medication. It’s also one of only two drugs shown to reduce suicidal thoughts, the other being lithium. Esketamine is administered in a clinical setting, not at home, and treatment involves periodic visits over weeks to months.
Transcranial magnetic stimulation (TMS) is another option for treatment-resistant cases, using targeted magnetic pulses to stimulate areas of the brain involved in mood regulation. It’s noninvasive, doesn’t require anesthesia, and is typically given as a series of sessions over several weeks.